Identification

Name
Lenalidomide
Accession Number
DB00480  (APRD01303)
Type
Small Molecule
Groups
Approved
Description

Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia] FDA approved on December 27, 2005.

Structure
Thumb
Synonyms
  • 1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
  • 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • CC-5013
  • CDC 501
  • IMid-1
  • IMiD3
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RevlimidCapsule20 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule20 mg/1OralCelgene2013-06-06Not applicableUs
RevlimidCapsule5 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule25 mgOralCelgene2008-10-10Not applicableCanada
RevlimidCapsule7.5 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule15 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule5 mg/1OralCelgene2005-12-27Not applicableUs
RevlimidCapsule5 mgOralCelgene2008-02-19Not applicableCanada
RevlimidCapsule5 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule2.5 mgOralCelgene2016-12-20Not applicableCanada
International/Other Brands
Ladevina / Lenangio / Revlimid
Categories
UNII
F0P408N6V4
CAS number
191732-72-6
Weight
Average: 259.2606
Monoisotopic: 259.095691297
Chemical Formula
C13H13N3O3
InChI Key
GOTYRUGSSMKFNF-UHFFFAOYSA-N
InChI
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
IUPAC Name
3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
SMILES
NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O

Pharmacology

Indication

Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Structured Indications
Pharmacodynamics

Lenalidomide, a thalidomide analogue, is an immunomodulatory agent possessing immunomodulatory and antiangiogenic properties. Lenalidomide inhibits the secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide inhibits cell proliferation with varying effectiveness (IC50s) in some but not all cell lines. Lenalidomide is effective in inhibiting growth of Namalwa cells (a human B cell lymphoma cell line with a deletion of one chromosome 5) but is much less effective in inhibiting growth of KG-1 cells (human myeloblastic cell line, also with a deletion of one chromosome 5) and other cell lines without chromosome 5 deletions. Lenalidomide does not prolong the QTc interval.

Mechanism of action

The mechanism of action of lenalidomide remains to be fully characterized, however it has been demonstrated that lenalidomide inhibits the expression of cyclooxygenase-2 (COX-2), but not COX-1, in vitro. In vivo it induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity

TargetActionsOrganism
AProtein cereblon
inhibitor
Human
ATumor necrosis factor ligand superfamily member 11
inhibitor
Human
UCadherin-5
antagonist
Human
UProstaglandin G/H synthase 2
negative modulator
Human
Absorption

Rapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (Cmax) by 36%. The pharmacokinetic disposition of lenalidomide is linear. Accumulation does not occur following multiple doses.

Volume of distribution
Not Available
Protein binding

30% protein bound.

Metabolism

Lenalidomide undergoes limited metabolism. Unchanged lenalidomide is the predominant circulating component in humans. Two identified metabolites are hydroxy-lenalidomide and N-acetyl-lenalidomide; each constitutes less than 5% of parent levels in circulation. The cytochrome P450 enzyme system is not involved with the metabolism of lenalidomide.

Route of elimination

Elimination is primarily renal. When a single oral dose of 25 mg is given healthy subjects, 90% and 4% of the dose is eliminated in urine and feces, respectively. Hydroxy-lenalidomide and N-acetyl-lenalidomide represent 4.59% and 1.83% of the excreted dose, respectively.

Half life

Healthy subjects = 3 hours; Multiple myeloma or MDS patients = 3 - 5 hours.

Clearance

The renal clearance of lenalidomide exceeds the glomerular filtration rate.

Toxicity

The most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Lenalidomide.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Lenalidomide.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Lenalidomide.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Lenalidomide.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lenalidomide.Approved
ChlorotrianiseneChlorotrianisene may increase the thrombogenic activities of Lenalidomide.Investigational, Withdrawn
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Lenalidomide.Approved
ClozapineThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Clozapine.Approved
Conjugated estrogensConjugated estrogens may increase the thrombogenic activities of Lenalidomide.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Lenalidomide.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Lenalidomide.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Lenalidomide.Experimental
DaidzeinDaidzein may increase the thrombogenic activities of Lenalidomide.Experimental
Darbepoetin alfaDarbepoetin alfa may increase the thrombogenic activities of Lenalidomide.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Lenalidomide.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Lenalidomide.Approved
DexamethasoneDexamethasone may increase the thrombogenic activities of Lenalidomide.Approved, Investigational, Vet Approved
DienestrolDienestrol may increase the thrombogenic activities of Lenalidomide.Approved, Investigational
DiethylstilbestrolDiethylstilbestrol may increase the thrombogenic activities of Lenalidomide.Approved, Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Lenalidomide.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lenalidomide.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lenalidomide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lenalidomide.Approved, Investigational
EpimestrolEpimestrol may increase the thrombogenic activities of Lenalidomide.Experimental
EquolEquol may increase the thrombogenic activities of Lenalidomide.Investigational
ErythropoietinErythropoietin may increase the thrombogenic activities of Lenalidomide.Approved
EstradiolEstradiol may increase the thrombogenic activities of Lenalidomide.Approved, Investigational, Vet Approved
EstriolEstriol may increase the thrombogenic activities of Lenalidomide.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may increase the thrombogenic activities of Lenalidomide.Approved
EstroneEstrone may increase the thrombogenic activities of Lenalidomide.Approved
Ethinyl EstradiolEthinyl Estradiol may increase the thrombogenic activities of Lenalidomide.Approved
FingolimodLenalidomide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Lenalidomide.Investigational
GenisteinGenistein may increase the thrombogenic activities of Lenalidomide.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Lenalidomide.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Lenalidomide.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Lenalidomide.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lenalidomide.Approved, Withdrawn
HexestrolHexestrol may increase the thrombogenic activities of Lenalidomide.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Lenalidomide.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Lenalidomide.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Lenalidomide.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Leflunomide.Approved, Investigational
LumacaftorThe serum concentration of Lenalidomide can be decreased when it is combined with Lumacaftor.Approved
MestranolMestranol may increase the thrombogenic activities of Lenalidomide.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Lenalidomide.Investigational, Withdrawn
MethallenestrilMethallenestril may increase the thrombogenic activities of Lenalidomide.Experimental
Methoxy polyethylene glycol-epoetin betaMethoxy polyethylene glycol-epoetin beta may increase the thrombogenic activities of Lenalidomide.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Lenalidomide.Experimental
MoxestrolMoxestrol may increase the thrombogenic activities of Lenalidomide.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Natalizumab.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Lenalidomide.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Lenalidomide.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lenalidomide.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Lenalidomide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lenalidomide.Approved, Investigational
Polyestradiol phosphatePolyestradiol phosphate may increase the thrombogenic activities of Lenalidomide.Approved
PromestrienePromestriene may increase the thrombogenic activities of Lenalidomide.Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Lenalidomide.Experimental
QuinestrolQuinestrol may increase the thrombogenic activities of Lenalidomide.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Lenalidomide.Approved
RanolazineThe serum concentration of Lenalidomide can be increased when it is combined with Ranolazine.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Lenalidomide.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Lenalidomide.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Lenalidomide.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Lenalidomide.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Lenalidomide.Approved
SecoisolariciresinolSecoisolariciresinol may increase the thrombogenic activities of Lenalidomide.Investigational
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Lenalidomide.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Lenalidomide.Investigational
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may increase the thrombogenic activities of Lenalidomide.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lenalidomide.Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Lenalidomide.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Lenalidomide.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Lenalidomide.Investigational
TiboloneTibolone may increase the thrombogenic activities of Lenalidomide.Approved, Investigational
TofacitinibLenalidomide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Lenalidomide.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Lenalidomide.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Lenalidomide.Approved
ZeranolZeranol may increase the thrombogenic activities of Lenalidomide.Vet Approved
Food Interactions
  • When given with a fatty meal, the extent of absorption is reduced.

References

Synthesis Reference

Surya Narayana Devarakonda, Sesha Reddy Yarraguntla, Vamsi Krishna Mudapaka, Rajasekhar Kadaboina, Veerender Murki, Amarendhar Manda, Venkata Rao Badisa, Naresh Vemula, Rama Seshagiri Rao Pulla, Venu Nalivela, "PREPARATION OF LENALIDOMIDE." U.S. Patent US20110021567, issued January 27, 2011.

US20110021567
General References
  1. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57. [PubMed:15703420]
  2. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006 Jul 15;108(2):618-21. Epub 2006 Mar 28. [PubMed:16569772]
  3. Anderson KC: Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. [PubMed:16344099]
External Links
Human Metabolome Database
HMDB14623
KEGG Drug
D04687
PubChem Compound
216326
PubChem Substance
46505725
ChemSpider
187515
BindingDB
50078323
ChEBI
63791
ChEMBL
CHEMBL848
Therapeutic Targets Database
DAP001255
PharmGKB
PA162363968
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lenalidomide
ATC Codes
L04AX04 — Lenalidomide
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (400 KB)
MSDS
Download (225 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic SciencePlasma Cell Myeloma1
0RecruitingTreatmentBlood And Marrow Transplantation / Leukemias / Malignant Lymphomas1
0TerminatedTreatmentAdult T-cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease / Leukemia, Adult T-Cell / Peripheral T-Cell Lymphoma (PTCL) / Peripheral T-cell Lymphoma Unspecified / T/Null Cell Systemic Type1
0TerminatedTreatmentMultiple Myeloma (MM)1
0Unknown StatusTreatmentMyelodysplasia1
1Active Not RecruitingPreventionSmoldering Multiple Myeloma (SMM)1
1Active Not RecruitingTreatmentAdenoidcystic Carcinoma / Neuroendocrine Tumors / Solid Organ Malignancies1
1Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAnaplastic Astrocytoma (AA) / Diffuse Intrinsic Pontine Glioma (DIPG) / High Grade Glioma (HGG)1
1Active Not RecruitingTreatmentAnn Arbor Stage II Grade 1 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage III Grade 1 Follicular Lymphoma / Ann Arbor Stage III Grade 2 Follicular Lymphoma / Ann Arbor Stage III Grade 3 Follicular Lymphoma / Ann Arbor Stage IV Grade 1 Follicular Lymphoma / Ann Arbor Stage IV Grade 2 Follicular Lymphoma / Ann Arbor Stage IV Grade 3 Follicular Lymphoma / CD20 Positive / Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
1Active Not RecruitingTreatmentAnn Arbor Stage III Small Lymphocytic Lymphoma / Ann Arbor Stage IV Small Lymphocytic Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma1
1Active Not RecruitingTreatmentB Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
1Active Not RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Leukemia, Prolymphocytic / Recurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma1
1Active Not RecruitingTreatmentCancer of the Urethra / Ureteral Cancer / Urethral Cancer / Urethral Neoplasms1
1Active Not RecruitingTreatmentExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL) / Primary Mediastinal B-Cell Lymphoma1
1Active Not RecruitingTreatmentHodgkins Disease (HD)1
1Active Not RecruitingTreatmentLeukemia Lymphocytic Chronic B-Cell1
1Active Not RecruitingTreatmentLeukemias2
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1Active Not RecruitingTreatmentLymphoma, Hodgkins1
1Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)2
1Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
1Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
1Active Not RecruitingTreatmentMultiple Myeloma in Relapse1
1Active Not RecruitingTreatmentPlasma Cell Myeloma1
1Active Not RecruitingTreatmentRecurrent Colon Carcinoma / Recurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Recurrent Rectal Carcinoma / Recurrent Salivary Gland Carcinoma / Salivary Gland Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 / Stage IVA Colon Cancer / Stage IVA Colon Cancer AJCC v7 / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVA Major Salivary Gland Cancer AJCC v7 / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVA Oral Cavity Cancer AJCC v6 and v7 / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Rectal Cancer / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Colon Cancer / Stage IVB Colon Cancer AJCC v7 / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVB Major Salivary Gland Cancer AJCC v7 / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVB Oral Cavity Cancer AJCC v6 and v7 / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Rectal Cancer / Stage IVB Rectal Cancer AJCC v7 / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVC Major Salivary Gland Cancer AJCC v7 / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVC Oral Cavity Cancer AJCC v6 and v7 / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Tongue Carcinoma / Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary1
1Active Not RecruitingTreatmentRecurrent Follicular Lymphoma1
1Active Not RecruitingTreatmentRefractory/Relapsed Indolent Non-Hodgkin Lymphoma1
1Active Not RecruitingTreatmentRelapsed/Refractory B-cell Lymphoma1
1CompletedNot AvailableHealthy Volunteers2
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Leukemia Acute Myeloid Leukemia (AML)1
1CompletedTreatmentAcute Myelogenous Leukaemia (AML)1
1CompletedTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With PML-RARA / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Alkylating Agent-Related Acute Myeloid Leukemia / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Leukemia, Prolymphocytic / Lymphomatous Involvement of Non-Cutaneous Extranodal Site / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Nodal Marginal Zone Lymphoma / Post-Transplant Lymphoproliferative Disorder / Primary Cutaneous B-Cell Non-Hodgkin Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides and Sezary Syndrome / Recurrent Non-Hodgkin Lymphoma / Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Richter's Syndrome / Small Intestinal Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentAdult T-cell lymphomas/leukaemias / Peripheral T-Cell Lymphoma (PTCL)1
1CompletedTreatmentAdvanced Cancer, Various, NOS1
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentAnemias / Chronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Thrombocytopenias1
1CompletedTreatmentBone Marrow Diseases / Chronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myeldysplastic Syndrome (MDS) / Neutropenias1
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Recurrent Childhood Brain Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma1
1CompletedTreatmentChildhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Secondary Myelodysplastic Syndromes / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Indolent Non-Hodgkin's Lymphomas / Mantle Cell Lymphoma (MCL)1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, B-Cell, Chronic1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentHealthy, Male1
1CompletedTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Melanoma1
1CompletedTreatmentMelanoma1
1CompletedTreatmentMultiple Myeloma (MM)12
1CompletedTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
1CompletedTreatmentMyelodysplasia1
1CompletedTreatmentMyelodysplastic Syndrome1
1CompletedTreatmentMyelodysplastic Syndromes1
1CompletedTreatmentMyelodysplastic Syndromes (MDS)1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentPlasma Cell Myeloma2
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentRelapsed Multiple Myeloma1
1CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
1CompletedTreatmentSmoldering Multiple Myeloma (SMM)1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1Not Yet RecruitingTreatmentBurkitt's Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
1Not Yet RecruitingTreatmentLymphoma, Hodgkins / Lymphoma, T-Cell, Cutaneous / Lymphoma, T-Cell, Peripheral1
1Not Yet RecruitingTreatmentMyelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Refractory High Risk Myelodysplastic Syndrome / Secondary Myelodysplastic Syndromes / Therapy-Related Myelodysplastic Syndrome1
1Not Yet RecruitingTreatmentNeuroblastomas1
1RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1RecruitingTreatmentAutoimmune Pancreatitis / IgG4-related Disease / IgG4-related Sclerosing Cholangitis / Immunoglobulin G Subclass 4 Related Disease / Retroperitoneal Fibrosis1
1RecruitingTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Grade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma1
1RecruitingTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / CD19 Positive / Mediastinal Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Mantle Cell Lymphoma / Refractory Small Lymphocytic Lymphoma1
1RecruitingTreatmentCLL / Richter's Syndrome1
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
1RecruitingTreatmentHaematological Malignancies / Plasma Cell Myeloma1
1RecruitingTreatmentHypercalcemia / Plasmacytoma / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1RecruitingTreatmentIntraocular Lymphoma / Recurrent/Refractory CNS1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome2
1RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1RecruitingTreatmentMultiple Myeloma (MM)4
1RecruitingTreatmentMyelodysplastic Syndromes / Myeloid Leukemias1
1RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentPartial Response of Multiple Myeloma or Plasma Cell Leukemia / Plasma Cell Myeloma1
1RecruitingTreatmentRelapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma1
1RecruitingTreatmentTumors, Central Nervous System1
1RecruitingTreatmentTumors, Solid1
1SuspendedTreatmentFollicular Lymphoma (FL)1
1SuspendedTreatmentLeukaemia, Acute1
1SuspendedTreatmentMultiple Myeloma (MM)2
1SuspendedTreatmentRecurrent Neuroblastoma / Refractory Neuroblastoma / Stage 4 Neuroblastoma1
1TerminatedTreatmentAcute Myelocytic Leukemia / Acute Myelogenous Leukaemia (AML) / Acute Non-Lymphocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML)1
1TerminatedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes1
1TerminatedTreatmentAdult Grade III Lymphomatoid Granulomatosis / Adult Non-Hodgkin's Lymphoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1TerminatedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1TerminatedTreatmentAdvanced Cancers1
1TerminatedTreatmentB-Cell Chronic Lymphocytic Leukemia1
1TerminatedTreatmentCancer, Ovarian / Fallopian Tube Carcinoma / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Lymphocytic, Chronic, B-Cell / Small Lymphocytic Lymphoma (SLL)1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Small Lymphocytic1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
1TerminatedTreatmentHepatocellular,Carcinoma1
1TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1TerminatedTreatmentMalignant Gliomas1
1TerminatedTreatmentMalignant Lymphomas / Multiple Myeloma (MM)1
1TerminatedTreatmentMalignant Neoplasm of Colon / Rectal Carcinoma1
1TerminatedTreatmentMultiple Myeloma (MM)1
1TerminatedTreatmentPlasma Cell Myeloma1
1TerminatedTreatmentProstate Cancer1
1TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1Unknown StatusTreatmentAdvanced Solid Tumors1
1WithdrawnTreatmentMalignant Neoplasms Stated as Primary Lymphoid Haematopoietic / Multiple Myeloma (MM)1
1, 2Active Not RecruitingTreatmentAIDS-Related Hodgkin Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentChronic Myelomonocytic Leukemia1
1, 2Active Not RecruitingTreatmentDiffuse Large B Cell Lymphoma Refractory / Diffuse Large B Cell Lymphoma Relapsed1
1, 2Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1, 2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas2
1, 2Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)12
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
1, 2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentPlasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma1
1, 2Active Not RecruitingTreatmentRecurrent Thyroid Gland Carcinoma / Stage I Thyroid Gland Follicular Carcinoma / Stage I Thyroid Gland Follicular Carcinoma AJCC v7 / Stage I Thyroid Gland Papillary Carcinoma / Stage I Thyroid Gland Papillary Carcinoma AJCC v7 / Stage II Thyroid Gland Follicular Carcinoma / Stage II Thyroid Gland Follicular Carcinoma AJCC v7 / Stage II Thyroid Gland Papillary Carcinoma / Stage II Thyroid Gland Papillary Carcinoma AJCC v7 / Stage III Thyroid Gland Follicular Carcinoma / Stage III Thyroid Gland Follicular Carcinoma AJCC v7 / Stage III Thyroid Gland Papillary Carcinoma / Stage III Thyroid Gland Papillary Carcinoma AJCC v7 / Stage IV Thyroid Gland Follicular Carcinoma / Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 / Stage IV Thyroid Gland Papillary Carcinoma / Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 / Stage IVA Thyroid Gland Follicular Carcinoma / Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 / Stage IVA Thyroid Gland Papillary Carcinoma / Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7 / Stage IVB Thyroid Gland Follicular Carcinoma / Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7 / Stage IVB Thyroid Gland Papillary Carcinoma / Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7 / Stage IVC Thyroid Gland Follicular Carcinoma / Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7 / Stage IVC Thyroid Gland Papillary Carcinoma / Stage IVC Thyroid Gland Papillary Carcinoma AJCC v71
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma2
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Smoldering Multiple Myeloma (SMM) / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Active Not RecruitingTreatmentRelapsed or Refractory / Relapsed or Refractory B- / T-Cell Lymphomas1
1, 2Active Not RecruitingTreatmentRelapsed/Refractory Mantle Cell Lymphoma1
1, 2CompletedNot AvailableCancer, Ovarian1
1, 2CompletedNot AvailableChronic Lymphocytic Leukaemia (CLL)1
1, 2CompletedTreatmentAdult Acute Myeloblastic Leukemia / Leukemia Acute Myeloid Leukemia (AML)1
1, 2CompletedTreatmentAmyloidosis1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / CLL1
1, 2CompletedTreatmentCancer Cachexia Syndrome1
1, 2CompletedTreatmentCarcinoma, Pancreatic1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)4
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, B-Cell / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL) / Waldenstrom's Macroglobulinemia (WM)1
1, 2CompletedTreatmentKaposi's Sarcoma AIDS Related / Recurrent Kaposi's Sarcoma1
1, 2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2CompletedTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
1, 2CompletedTreatmentLow- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)1
1, 2CompletedTreatmentMalignancies, Hematologic / Multiple Myeloma (MM)1
1, 2CompletedTreatmentMalignant Lymphomas2
1, 2CompletedTreatmentMantle Cell Lymphoma (MCL)1
1, 2CompletedTreatmentMultiple Myeloma (MM)6
1, 2CompletedTreatmentPlasma Cell Myeloma1
1, 2CompletedTreatmentPlasma Cell Myeloma / Transplantation, Stem Cell1
1, 2CompletedTreatmentProstate Cancer2
1, 2CompletedTreatmentRecurrent Ovarian Cancer1
1, 2CompletedTreatmentRefractory Multiple Myeloma / Relapses1
1, 2CompletedTreatmentWaldenstrom's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Recurrent Adult Acute Myeloid Leukemia1
1, 2RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Untreated Hairy Cell Leukemia / Waldenstrom's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage II Angioimmunoblastic T-cell Lymphoma / Stage II Enteropathy-Associated T-Cell Lymphoma / Stage III Angioimmunoblastic T-cell Lymphoma / Stage III Enteropathy-Associated T-Cell Lymphoma / Stage IV Angioimmunoblastic T-cell Lymphoma / Stage IV Enteropathy-Associated T-Cell Lymphoma1
1, 2RecruitingTreatmentCD20 Positive / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma1
1, 2RecruitingTreatmentCancer, Advanced1
1, 2RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Multiple Myeloma (MM) / Plasma Cell Myeloma1
1, 2RecruitingTreatmentFollicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) / Follicular Lymphoma Patients (Phase IB)1
1, 2RecruitingTreatmentFolliculotropic Mycosis Fungoides / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides / Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory Mycosis Fungoides / Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified / Sezary Syndrome1
1, 2RecruitingTreatmentIndolent Plasma Cell Myeloma / Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
1, 2RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell / Malignant Lymphomas1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Relapsed or Refractory Solid Tumors1
1, 2RecruitingTreatmentLymphoma, B Cell / Malignant Lymphomas1
1, 2RecruitingTreatmentLymphoma, B-Cell1
1, 2RecruitingTreatmentLymphoma, B-Cell / Primary Effusion Lymphomas1
1, 2RecruitingTreatmentMalignant Lymphomas4
1, 2RecruitingTreatmentMultiple Myeloma (MM)5
1, 2RecruitingTreatmentPlasma Cell Leukemia in Remission / Plasma Cell Myeloma1
1, 2RecruitingTreatmentPlasma Cell Myeloma1
1, 2RecruitingTreatmentRecurrent Chronic Lymphocytic Leukemia1
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma1
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2RecruitingTreatmentRefractory Diffuse Large B-Cell Lymphoma / Relapsed Diffuse Large B-Cell Lymphoma1
1, 2RecruitingTreatmentRelapsed Hodgkin Lymphoma / Relapsed Non-Hodgkin's Lymphoma1
1, 2SuspendedTreatmentGrade 3a Follicular Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Waldenstrom Macroglobulinemia / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma1
1, 2TerminatedTreatmentAggressive Marginal Zone Lymphoma (MZL) / Burkitt Lymphoma (BL) / Follicular Lymphoma Grade III (FL III°) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL), Blastoid Variant1
1, 2TerminatedTreatmentCancer, Ovarian1
1, 2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1, 2TerminatedTreatmentLow to Intermediate-1 MDS / Myelodysplastic Syndrome / Non-deletion 5q / Smith-Magenis Syndrome1
1, 2TerminatedTreatmentLymphoma, Hodgkins / Mature T-cell Lymphoma / Multiple Myeloma (MM)1
1, 2TerminatedTreatmentMalignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentMultiple Myeloma (MM)1
1, 2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2TerminatedTreatmentPeripheral T-Cell Non-Hodgkin's Lymphoma1
1, 2TerminatedTreatmentRelapsed Or Refractory Multiple Myeloma1
1, 2TerminatedTreatmentRenal Cell Adenocarcinoma1
1, 2TerminatedTreatmentUrinary Bladder Neoplasms1
1, 2Unknown StatusTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer1
1, 2Unknown StatusTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Unknown StatusTreatmentAmyloidosis1
1, 2Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
1, 2Unknown StatusTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone B-Cell Lymphoma1
1, 2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Unknown StatusTreatmentMultiple Myeloma (MM)4
1, 2Unknown StatusTreatmentTumors, Solid1
1, 2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2WithdrawnTreatmentFollicular Lymphoma (FL) / Malignant Lymphomas1
1, 2WithdrawnTreatmentMultiple Myeloma (MM)2
1, 2WithdrawnTreatmentMyeloma Multiple1
2Active Not RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Leukemia Acute Myeloid Leukemia (AML)1
2Active Not RecruitingTreatmentAdult Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Chronic Myelomonocytic Leukemia-1 / Chronic Myelomonocytic Leukemia-2 / Previously Treated Myelodysplastic Syndromes / Refractory Anemia With Excess Blasts1
2Active Not RecruitingTreatmentAdult T-cell lymphomas/leukaemias1
2Active Not RecruitingTreatmentAdvanced Myeloma / Plasma Cell Myeloma1
2Active Not RecruitingTreatmentAgnogenic Myeloid Metaplasia1
2Active Not RecruitingTreatmentAnn Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / CD20 Positive / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
2Active Not RecruitingTreatmentBladder Cancers1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / CLL1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)2
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)3
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma1
2Active Not RecruitingTreatmentChronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma of Mucosa-Associated Lymphoid Tissue / Lymphoma, Mantle-Cell / MALT Lymphoma / Marginal Zone B-Cell Lymphoma / Small Lymphocytic Lymphoma (SLL) / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentLenalidomide / Malignant Lymphomas / Relapses / Rituximab1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingTreatmentLymphoma, Mantle-Cell / Mantle Cell Lymphoma (MCL)1
2Active Not RecruitingTreatmentMalignant Lymphomas5
2Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)2
2Active Not RecruitingTreatmentMultiple Myeloma (MM)24
2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Renal Failure1
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2Active Not RecruitingTreatmentMyelodysplastic Syndrome3
2Active Not RecruitingTreatmentMyelodysplastic Syndromes3
2Active Not RecruitingTreatmentMyelodysplastic Syndrome / Smith-Magenis Syndrome1
2Active Not RecruitingTreatmentMyeloid Leukemias1
2Active Not RecruitingTreatmentMyeloproliferative Disorders1
2Active Not RecruitingTreatmentNeoplasms, Thyroid1
2Active Not RecruitingTreatmentNeurofibromatosis Type 1 / Recurrent Childhood Pilocytic Astrocytoma / Recurrent Childhood Visual Pathway Glioma1
2Active Not RecruitingTreatmentNewly Diagnosed Multiple Myeloma1
2Active Not RecruitingTreatmentNon Hodgkin Lymphoma (NHL)1
2Active Not RecruitingTreatmentPlasma Cell Myeloma2
2Active Not RecruitingTreatmentProstate Cancer1
2Active Not RecruitingTreatmentRecurrent Mantle Cell Lymphoma1
2Active Not RecruitingTreatmentSmoldering Multiple Myeloma (SMM) / Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic Multiple Myeloma1
2Active Not RecruitingTreatmentSmoldering Multiple Myeloma (SMM) / Smoldering Myeloma1
2Active Not RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma2
2CompletedNot AvailableImpaired Renal Function / Multiple Myeloma (MM)1
2CompletedNot AvailablePlasma Cell Dyscrasia1
2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome1
2CompletedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
2CompletedTreatmentAdult T Cell Leukemia/Lymphoma1
2CompletedTreatmentAgnogenic Myeloid Metaplasia1
2CompletedTreatmentAmyloidosis2
2CompletedTreatmentAngiogenesis / Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes1
2CompletedTreatmentAutism, Early Infantile1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / CLL / Leukemias / Small Lymphocytic Lymphoma (SLL)1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)5
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias2
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)3
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia1
2CompletedTreatmentComplex Regional Pain Syndrome (RSD)1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2CompletedTreatmentEssential Thrombocythemia (ET) / Polycythemia Vera (PV) / Primary Myelofibrosis1
2CompletedTreatmentFollicular Lymphoma (FL)1
2CompletedTreatmentGlioblastomas / Gliosarcoma / Malignant Gliomas1
2CompletedTreatmentHematologic Cancers1
2CompletedTreatmentHodgkins Disease (HD)2
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)4
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Smith-Magenis Syndrome1
2CompletedTreatmentLeukemia, Lymphocytic / Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentLeukemia, Lymphocytic / Precursor B-Cell Lymphoblastic Leukemia-Lymphoma1
2CompletedTreatmentLeukemias1
2CompletedTreatmentLeukemias / Malignant Lymphomas1
2CompletedTreatmentLiver Cancer2
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentLymphoma of the Mucosa Associated Lymphoid Tissue (MALT)1
2CompletedTreatmentMalignant Lymphomas3
2CompletedTreatmentMantle Cell Lymphoma (MCL)2
2CompletedTreatmentMelanoma1
2CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
2CompletedTreatmentMultiple Myeloma (MM)24
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm4
2CompletedTreatmentMyelodysplastic Syndrome2
2CompletedTreatmentMyelodysplastic Syndromes5
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)3
2CompletedTreatmentPOEMS Syndrome2
2CompletedTreatmentPancreatic Cancer Metastatic1
2CompletedTreatmentPrimary Plasma Cell Leukemia1
2CompletedTreatmentPrimary Systemic Amyloidosis1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2CompletedTreatmentRefractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)1
2CompletedTreatmentRelapsed or Refractory Chronic Lymphocytic Leukemia1
2CompletedTreatmentRenal Cancers2
2CompletedTreatmentSquamous Cell Carcinoma (SCC)1
2CompletedTreatmentStage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
2CompletedTreatmentT-Cell Lymphomas1
2CompletedTreatmentLight chain amyloidosis1
2Not Yet RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2Not Yet RecruitingTreatmentEBV Related Non-Hodgkin's Lymphoma / Primary Central Nervous System Lymphoma (PCNSL) / Primary Testicular Lymphoma1
2Not Yet RecruitingTreatmentHematopoietic/Lymphoid Cancer / Mantle Cell Lymphoma (MCL)1
2Not Yet RecruitingTreatmentMucosa Associated Lymphoid Tissue (MALT) Lymphoma1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)2
2Not Yet RecruitingTreatmentPlasma Cell Myeloma1
2Not Yet RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2Not Yet RecruitingTreatmentSmoldering Multiple Myeloma (SMM)1
2RecruitingSupportive CareMultiple Myeloma (MM)1
2RecruitingTreatmentAdult Myelodysplastic Syndrome / Anemias / Chronic Myelomonocytic Leukemia1
2RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome1
2RecruitingTreatmentB-cell Non-Hodgkin's Lymphomas1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)2
2RecruitingTreatmentFollicular Lymphoma (FL)1
2RecruitingTreatmentFollicular Lymphoma (FL) / Malignant Lymphomas1
2RecruitingTreatmentGrade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Follicular Lymphoma / Refractory Follicular Lymphoma1
2RecruitingTreatmentHistiocytic Sarcoma (HS) / Histiocytoses Erdheim-chester Disease / Langerhans Cell Histiocytosis (LCH)1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes1
2RecruitingTreatmentLeukemia, Lymphocytic / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentLeukemias2
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentMalignant Lymphomas1
2RecruitingTreatmentMalignant Lymphomas / Neurotoxicity / Therapy-Related Toxicity1
2RecruitingTreatmentMantle Cell Lymphoma (MCL) / Untreated1
2RecruitingTreatmentMonoclonal B-Cell Lymphocytosis / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma1
2RecruitingTreatmentMultiple Myeloma (MM)15
2RecruitingTreatmentMyelodysplastic Syndromes1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentPOEMS Syndrome1
2RecruitingTreatmentPlasmacytoma / POEMS Syndrome1
2RecruitingTreatmentPlasma Cell Myeloma3
2RecruitingTreatmentPlasma Cell Myeloma / Residual Disease1
2RecruitingTreatmentPlasma Cell Myeloma / Transplant-Related Carcinoma1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Multiple Myeloma / Refractory Plasma Cell Myeloma1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2RecruitingTreatmentRecurrent Primary Amyloidosis1
2RecruitingTreatmentRelapse/Refractory Multiple Myeloma1
2RecruitingTreatmentRelapsed/Refractory Mantle Cell Lymphoma1
2RecruitingTreatmentSmith-Magenis Syndrome1
2RecruitingTreatmentSmoldering Multiple Myeloma (SMM)2
2RecruitingTreatmentT-Cell Lymphomas1
2SuspendedSupportive CareNeuropathy / Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)1
2SuspendedTreatmentContiguous Stage II Small Lymphocytic Lymphoma / Leukemia, Prolymphocytic / Noncontiguous Stage II Small Lymphocytic Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma1
2TerminatedOtherHaematological disorders1
2TerminatedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes1
2TerminatedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Leukemia, Prolymphocytic / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2TerminatedTreatmentCancer, Advanced / Pain1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)4
2TerminatedTreatmentChronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)1
2TerminatedTreatmentColorectal Cancers1
2TerminatedTreatmentComplex Regional Pain Syndrome, Type I1
2TerminatedTreatmentFollicular Lymphoma (FL) / Marginal Zone Lymphoma1
2TerminatedTreatmentGraft Versus Host Disease (GVHD)1
2TerminatedTreatmentHIV Infection Associated Kaposi Disease1
2TerminatedTreatmentIntraocular Melanoma / Malignant Conjunctival Neoplasm1
2TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndromes (MDS)1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Relapsed Adult Acute Lymphocytic Leukemia1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentMultiple Myeloma (MM)3
2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2TerminatedTreatmentMyelodysplastic Syndrome MDS1
2TerminatedTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2TerminatedTreatmentRefractory Plasma Cell Myeloma1
2TerminatedTreatmentSmith-Magenis Syndrome1
2TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2TerminatedTreatmentWaldenstrom's Macroglobulinemia (WM)2
2Unknown StatusTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome1
2Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL) / CLL / First-Line / Front-line / Initial Therapy / Untreated1
2Unknown StatusTreatmentCutaneous T Cell Lymphomas (CTCL)1
2Unknown StatusTreatmentIndolent Non Hodgkin Lymphoma1
2Unknown StatusTreatmentLeukemias1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2Unknown StatusTreatmentMALT Lymphoma1
2Unknown StatusTreatmentMalignant Lymphomas2
2Unknown StatusTreatmentMultiple Myeloma (MM)3
2Unknown StatusTreatmentMyelodysplastic Syndrome1
2Unknown StatusTreatmentMyelodysplastic Syndromes1
2Unknown StatusTreatmentPOEMS Syndrome1
2Unknown StatusTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL)1
2WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL) / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia1
2WithdrawnTreatmentLeukemias / Malignant Lymphomas1
2WithdrawnTreatmentMalignant Gliomas1
2WithdrawnTreatmentMultiple Myeloma (MM)3
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2, 3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2, 3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
2, 3CompletedTreatmentMultiple Myeloma (MM)1
2, 3CompletedTreatmentRadicular syndrome1
3Active Not RecruitingBasic ScienceNewly Diagnosed, Previously Untreated Multiple Myeloma1
3Active Not RecruitingTreatmentAnemias1
3Active Not RecruitingTreatmentAnemias / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes1
3Active Not RecruitingTreatmentB-Cell Chronic Lymphocytic Leukemia1
3Active Not RecruitingTreatmentB-Cell Chronic Lymphocytic Leukemia / B-Cell Chronic Lymphocytic Leukemia (B-CLL)1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL)2
3Active Not RecruitingTreatmentLight Chain Deposition Disease / Smoldering Plasma Cell Myeloma1
3Active Not RecruitingTreatmentLymphoma (Myeloma) / Malignant Lymphomas / Multiple Myeloma (MM)1
3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas1
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)11
3Active Not RecruitingTreatmentMultiple Myeloma (MM) / Newly Diagnosed Patients1
3Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentPlasma Cell Myeloma2
3Active Not RecruitingTreatmentPreviously Untreated Symptomatic Multiple Myeloma1
3Active Not RecruitingTreatmentRefractory Multiple Myeloma / Relapsed Multiple Myeloma1
3Active Not RecruitingTreatmentRelapsed Multiple Myeloma1
3Active Not RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3CompletedDiagnosticMultiple Myeloma (MM)1
3CompletedPreventionMelanoma / Neoplasms Metastasis1
3CompletedTreatmentMultiple Myeloma (MM)11
3CompletedTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
3CompletedTreatmentMyelodysplastic Syndromes1
3CompletedTreatmentNewly Diagnosed Multiple Myeloma1
3CompletedTreatmentProstate Cancer1
3CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
3Not Yet RecruitingTreatmentPlasmacytoma1
3RecruitingTreatmentFollicular Lymphoma (FL)1
3RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3RecruitingTreatmentMultiple Myeloma (MM)7
3RecruitingTreatmentMyelodysplastic Syndrome1
3RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentPlasma Cell Myeloma1
3RecruitingTreatmentRelapsed or Refractory Systemic Light Chain Amyloidosis1
3RecruitingTreatmentSolitary Osseous Plasmacytoma1
3RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3SuspendedTreatmentMultiple Myeloma (MM)1
3TerminatedTreatmentMalignant Lymphomas1
3TerminatedTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
3TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3WithdrawnTreatmentBlood Protein Disorders / Hematologic Diseases / Multiple Myeloma (MM) / Neoplasms / Paraproteinemias / Plasma Cells / Therapeutic Uses1
4Active Not RecruitingTreatmentMultiple Myeloma (MM)2
4CompletedTreatmentCutaneous Lupus1
4RecruitingTreatmentMultiple Myeloma (MM)1
4TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
Not AvailableActive Not RecruitingTreatmentCLL / Leukemias1
Not AvailableActive Not RecruitingTreatmentMultiple Myeloma (MM)1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM)1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
Not AvailableCompletedNot AvailableMultiple Myeloma (MM)2
Not AvailableCompletedNot AvailableMyelodysplastic Syndrome1
Not AvailableCompletedTreatmentAmyloidosis / Leukemias1
Not AvailableCompletedTreatmentAnemias / Dysmyelopoietic Syndromes / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Myelocytic, Acute / Leukemias / Myelodysplastic Syndromes (MDS)1
Not AvailableCompletedTreatmentCutaneous Lupus Erythematosus (CLE)1
Not AvailableCompletedTreatmentMultiple Myeloma (MM)1
Not AvailableRecruitingNot AvailableMalignant Lymphomas1
Not AvailableRecruitingNot AvailableMultiple Myeloma (MM)2
Not AvailableRecruitingNot AvailableMyelodysplastic Syndrome / Myelodysplastic Syndromes (MDS)1
Not AvailableTerminatedNot AvailableMultiple Myeloma (MM)1
Not AvailableTerminatedTreatmentB-Cell Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia1
Not AvailableTerminatedTreatmentPlasma Cell Myeloma1

Pharmacoeconomics

Manufacturers
  • Celgene corp
  • Celgene Corporation
Packagers
Dosage forms
FormRouteStrength
CapsuleOral10 mg/1
CapsuleOral10 mg
CapsuleOral15 mg/1
CapsuleOral15 mg
CapsuleOral2.5 mg/1
CapsuleOral2.5 mg
CapsuleOral20 mg/1
CapsuleOral20 mg
CapsuleOral25 mg
CapsuleOral25 mg/1
CapsuleOral5 mg
CapsuleOral5 mg/1
CapsuleOral7.5 mg
Prices
Unit descriptionCostUnit
Revlimid 25 mg capsule411.71USD capsule
Revlimid 15 mg capsule407.7USD capsule
Revlimid 10 mg capsule406.05USD capsule
Revlimid 5 mg capsule388.0USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2477301No2009-09-012023-04-13Canada
CA2342974No2005-08-162014-02-24Canada
US6045501No1998-08-282018-08-28Us
US6315720No2000-10-232020-10-23Us
US6561976No1998-08-282018-08-28Us
US6561977No2000-10-232020-10-23Us
US6755784No2000-10-232020-10-23Us
US6908432No1998-08-282018-08-28Us
US8204763No1998-08-282018-08-28Us
US8315886No2000-10-232020-10-23Us
US8626531No2000-10-232020-10-23Us
US8589188No1998-08-282018-08-28Us
US7468363No2003-10-072023-10-07Us
US6281230No1996-07-242016-07-24Us
US8530498No2003-05-152023-05-15Us
US6555554No1996-07-242016-07-24Us
US7189740No2003-04-112023-04-11Us
US7968569No2003-10-072023-10-07Us
US8404717No2003-04-112023-04-11Us
US8648095No2003-05-152023-05-15Us
US8741929No2008-03-082028-03-08Us
US9101622No2003-05-152023-05-15Us
US9101621No2003-05-152023-05-15Us
US9056120No2003-04-112023-04-11Us
US5635517No1999-10-042019-10-04Us
US7119106No1996-07-242016-07-24Us
US7465800No2007-04-272027-04-27Us
US7855217No2004-11-242024-11-24Us
US8288415No1996-07-242016-07-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySoluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/mL.Not Available
logP-0.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.33 mg/mLALOGPS
logP-0.43ALOGPS
logP-0.71ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)11.61ChemAxon
pKa (Strongest Basic)2.31ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.5 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity68.3 m3·mol-1ChemAxon
Polarizability25.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9958
Blood Brain Barrier+0.9372
Caco-2 permeable-0.5981
P-glycoprotein substrateSubstrate0.6845
P-glycoprotein inhibitor IInhibitor0.6012
P-glycoprotein inhibitor IINon-inhibitor0.8927
Renal organic cation transporterNon-inhibitor0.726
CYP450 2C9 substrateNon-substrate0.8861
CYP450 2D6 substrateNon-substrate0.7878
CYP450 3A4 substrateSubstrate0.5855
CYP450 1A2 substrateNon-inhibitor0.8746
CYP450 2C9 inhibitorNon-inhibitor0.8405
CYP450 2D6 inhibitorNon-inhibitor0.8806
CYP450 2C19 inhibitorNon-inhibitor0.78
CYP450 3A4 inhibitorNon-inhibitor0.7469
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.843
Ames testNon AMES toxic0.8268
CarcinogenicityNon-carcinogens0.9068
BiodegradationNot ready biodegradable0.9967
Rat acute toxicity2.5145 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9803
hERG inhibition (predictor II)Non-inhibitor0.5098
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-1920000000-c10c48acd9b8123e3505

Taxonomy

Description
This compound belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoindoles and derivatives
Sub Class
Isoindolines
Direct Parent
Isoindolones
Alternative Parents
Alpha amino acids and derivatives / Isoindoles / Piperidinediones / Delta lactams / Benzenoids / Tertiary carboxylic acid amides / N-unsubstituted carboxylic acid imides / Dicarboximides / Azacyclic compounds / Primary amines
show 4 more
Substituents
Alpha-amino acid or derivatives / Isoindolone / Isoindole / Piperidinedione / Delta-lactam / Piperidinone / Piperidine / Benzenoid / Carboxylic acid imide / Dicarboximide
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
dicarboximide, aromatic amine, piperidones, isoindoles (CHEBI:63791)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Norma...
Gene Name
CRBN
Uniprot ID
Q96SW2
Uniprot Name
Protein cereblon
Molecular Weight
50545.375 Da
References
  1. Zhu YX, Kortuem KM, Stewart AK: Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. doi: 10.3109/10428194.2012.728597. Epub 2012 Sep 28. [PubMed:22966948]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Tumor necrosis factor receptor superfamily binding
Specific Function
Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be...
Gene Name
TNFSF11
Uniprot ID
O14788
Uniprot Name
Tumor necrosis factor ligand superfamily member 11
Molecular Weight
35477.81 Da
References
  1. Akobeng AK, Stokkers PC: Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351. doi: 10.1002/14651858.CD007351.pub2. [PubMed:19370685]
  2. Melchert M, List A: The thalidomide saga. Int J Biochem Cell Biol. 2007;39(7-8):1489-99. Epub 2007 Jan 30. [PubMed:17369076]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor binding
Specific Function
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of hete...
Gene Name
CDH5
Uniprot ID
P33151
Uniprot Name
Cadherin-5
Molecular Weight
87527.715 Da
References
  1. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB: The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009 Mar;77(2):78-86. doi: 10.1016/j.mvr.2008.08.003. Epub 2008 Sep 4. [PubMed:18805433]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Negative modulator
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004 Aug;230(2):81-8. [PubMed:15598423]
  2. Zeldis JB, Schafer PH, Bennett BL, Mercurio F, Stirling DI: Potential new therapeutics for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr;30(2):275-81. [PubMed:12720152]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18